Clinical Trial

Nicotinamide Riboside Clinical Trial for GWI

Recruiting
View on ClinicalTrials.gov →
Summary
In this multi-site trial, we will use a randomized, double-blind, placebo-controlled study design to test whether 300 mg of Nicotinamide Riboside (NR) can achieve the primary objective of increasing plasma NAD+ levels in participants with Gulf War Illness (GWI).
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2022-02-14; most recent amendment 2025-07-21.
Status change: Not Yet Recruiting → Recruiting 2022-04-25
Trial Details
NCT Number NCT05243290
Lead Sponsor Roskamp Institute Inc.
Collaborators: United States Department of Defense, Nova Southeastern University
Conditions Gulf War Illness
Enrollment 52 participants
Start Date 2022-04-13
Primary Completion 2025-04-30 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-07-24